REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates ...

The collaboration will put together the MoxiePlex multiplex fluorescence technology with InSituPlex, Vizgen's proprietary sample preparation technique in which a mixture of antibodies are "barcoded" ...